抗乙型肝炎病毒耐药及防治策略

参 考 文 献
[1] Hoofnagle J H,Doo E,Liang T J ,et al.Management of hepatitis B:Summary of a clinical Research workshop Hepatology 2007,45:1056-1075.
[2]Lok As,Lai C L,Leung N,et al.Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003,125:1714-1722.
[3]Hadgiyannis S,Tessopoulos N,Chang T J,et al.long-term adefovir dipivoxil treatment induces regression of liver fibrosis in patients with HBeAg-negative chronic hepatitis B:results after 5 years of fherapy Hepatology 2005,42:754A
[4]Locarnini S,HBV DRUG RESISTANCE Antivir.Ther.2006;11:4.
[5]Nowak M A,Bonhoeffer S.Hill A M,et al.Viral dynamics in hepatitis B virus infection.Proc Natl Acad Sci USA,1996,93:4398-44 02.
[6]Locarninis Mason W.S.Cellular and virological machanisms of HBV drug resistance Hepatology 2006 ,44:422-431.
[7]Zoulin F.Antiviral therapy of chronic hepatitis B .Antiviral Res.2006,1(2-3):206-215.
[8]Lok A S,Zoulim F,Locarnini S,et al:Antiviral Drug-Resistant HBV:Standardigation of Nomenclature and Assays and Recommendation for Management. Hepatology.2007；46：254-265.
[9]Lai C L,Leung N,Teo E K,et al.A 1-year trial of telbivudine,lamivudine,and the combination in patients with HBeAg-positive chronic hepatitis B.Gastroentorology 2005,129(2):528-536.
[10]Yatsvji H,Noguchi C,Hiraga N,et al.Emergence of a noval lamivudine-resistant hepatitis B virus viriant with a substitution outside the YMDD motif.Antimicrob Agents chemother.2006,50(11):3867-3874.
[11]Schildgen O,Sirma H,Funk A,et al.Variant of hepatitis B virus with primary resistance to adefovir.N Engl J Med,2006,354(17):1807-1812.
[12]Tenney D J,Levine S M,Rose R E,et al.Clinical emergence of enticarir-resistant hepatitis B Virus reguires additional substitutio-ns in virus already resistant to lamivudine.Antimicrob Agents Chem-other.2004,48:3498-3507.
[13]Tenney D J,Rose R E.Baldick C J.et al.Two-year assessment of enticavir resistance in lamivudinerefractory hepatitis B virus patients reveals different clinical outcomes depending on the Resistance substitutions present.Antimicrob Agents Chemother 2007.51:902-911.
[14]Locanini S 慢性乙型肝炎抗病毒耐药及其处理 肝脏，2007，12（3）：161-163.
[15]Colonno R J.Four years Assessment of enticavir Resistance In nucleoside-Naive and lamivudine refratory Patients.Hepatology 2006,suppl.1.46(4):S293 .
[16]Masao Omata.中国医学论坛报.2008.3.20.A8版.
[17]Sung JJY,Lai J Y.Zeuzem S et al.A randomised double-blind phase II study of lamivudine compared to lamivudine Plus adefovir dipovoxil for treatment naive patients with chronic he-patitis B:week 52 analysis.Hepatology 2003,38(suppl 2):25-26.
[18]贾继东.侯全林.尹有宽等.替比夫定或拉米夫定抗乙型肝炎病毒的疗效预测探讨  中华肝脏病杂志.2007,15(5):342-345.
[19]Di Bisceglie A,Lai C L,Game E,et al,Telbivudine Globe tri-al.Hepatology 2006,44(4,suppl 1):230A.
[20]Keeffe E,Zeuzem S,Koff R.et al.Report of an international workshoop:roadmap for management of patients receiviing oral the-rapy for chronic hepatitis B.Clin.Gastroenterol Hepatol.2007,5:890-897.
[21]Gish R.乙肝治疗策略及最新进展 中国医学论坛报  2008.2.21 D6版.
[22]Lampertico P.Vigano M.Manenti E,et al.Adefovir rapidly s-uppersses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine.Hepatology 2005,42:1414-1419.
[23]Yun Fan Liaw.Rescue therapy for lamivudineresistant chronic hepatitis B:When and How?Hepatology 2007,45(2):266-268.
[24]Peters M G,Hann H W,Mutimer D,et al.Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.Gastroenterology 2004,126:91-101.
[25]Liaw Y F.Lee C M.Chien R N,et al.Switching to adefovir monotherapy after emergence of lamivudine resistant mutations in patients with liver cirrhosis.J Viral Hepat.2006,13:250-255.
[26]Fung S K,Chae H B,Fontance R J,et al.Virologic response and resistance to adefovir in patients with chronic hepatitis B.Hepatology 2006,44:283-290.
[27]Yeon J E.Yoo W.Hong S P,et al.Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B treated with adefovir dipivoxil.Gut 2006,55:1488-1495.
[28]Rapti I,Dimou E,Mitsoula P,et al.Adding-on Versus Switching-to Adefovir Therapy in lamivudine-resistant HBeAg- negative Chronic hepatitis B.Hepatology 2007,45(2):307-313.